Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan;82(1):87-92.
doi: 10.1007/s40265-021-01648-1.

Chiglitazar: First Approval

Emma D Deeks  1
Affiliations
Review

Chiglitazar: First Approval

Emma D Deeks. Drugs. 2022 Jan.

Abstract

Chiglitazar (Bilessglu®) is an orally administered, non-thiazolidinedione small-molecule agonist of α, δ and γ peroxisome proliferator-activated receptors (PPARs) being developed by Chipscreen Biosciences for the treatment of type 2 diabetes (T2D) and non-alcoholic steatohepatitis. In October 2021, chiglitazar was approved in China for use as an adjunct to diet and exercise to improve glycaemic control in adult patients with T2D. The drug is also in phase 2 clinical development in China for the treatment of non-alcoholic steatohepatitis. This article summarizes the milestones in the development of chiglitazar leading to this first approval for the treatment of T2D.

PubMed Disclaimer

References

    1. Dubois V, Eeckhoute J, Lefebvre P, et al. Distinct but complementary contributions of PPAR isotypes to energy homeostasis. J Clin Invest. 2017;127(4):1202–14. - DOI
    1. Cheng HS, Tan WR, Low ZS, et al. Exploration and development of PPAR modulators in health and disease: an update of clinical evidence. Int J Mol Sci. 2019;20(20):11. - DOI
    1. Li PP, Shan S, Chen YT, et al. The PPAR α/γ dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. Brit J Pharmacol. 2006;148(5):610–8. - DOI
    1. He BK, Ning ZQ, Li ZB, et al. In vitro and in vivo characterizations of chiglitazar, a newly identified PPAR pan-agonist. PPAR Res. 2012. https://doi.org/10.1155/2012/546548 . - DOI - PubMed - PMC
    1. Chipscreen Biosciences. Chiglitazar (Bilessglu®): Chinese prescribing information. 2021.

MeSH terms

LinkOut - more resources